Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
992.60B
Market cap992.60B
Price-Earnings ratio
45.84
Price-Earnings ratio45.84
Dividend yield
0.57%
Dividend yield0.57%
Average volume
3.14M
Average volume3.14M
High today
$1,051.99
High today$1,051.99
Low today
$1,014.39
Low today$1,014.39
Open price
$1,019.17
Open price$1,019.17
Volume
4.33M
Volume4.33M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 992.6B, Eli Lilly(LLY) trades at $1,048.25. The stock has a price-to-earnings ratio of 45.84 and currently yields dividends of 57.0%.

On 2026-02-28, Eli Lilly(LLY) stock moved within a range of $1,014.39 to $1,051.99. With shares now at $1,048.25, the stock is trading +3.3% above its intraday low and -0.4% below the session's peak.

Trading volume for Eli Lilly(LLY) stock has reached 4.33M, versus its average volume of 3.14M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

LLY News

Simply Wall St 30m
A Look At Eli Lilly Valuation After GLP‑1 Trial Wins And Obesity Franchise Progress

Eli Lilly (LLY) is back in focus after fresh clinical data showed its injectable GLP-1 drug tirzepatide and oral candidate orforglipron outperforming Novo Nordi...

A Look At Eli Lilly Valuation After GLP‑1 Trial Wins And Obesity Franchise Progress
Simply Wall St 1d
Eli Lilly Advances Oral GLP 1 And Immunology Growth Story

Eli Lilly (NYSE:LLY) reported that its oral GLP-1 candidate orforglipron outperformed Novo Nordisk’s oral semaglutide in a head to head Phase 3 trial in adults...

Eli Lilly Advances Oral GLP 1 And Immunology Growth Story
The Wall Street Journal 1d
Watch: Why Eli Lilly Is Winning the Weight-Loss War

WSJ Heard on the Street columnist David Wainer breaks down why Novo Nordisk has struggled and Eli Lilly has prospered in the weight-loss drug market....

Watch: Why Eli Lilly Is Winning the Weight-Loss War

Analyst ratings

79%

of 34 ratings
Buy
79.4%
Hold
17.6%
Sell
2.9%

More LLY News

TipRanks 1d
Innovent Wins China Approval for New Jaypirca Leukemia Indication

Innovent Biologics ( (HK:1801) ) just unveiled an update. Innovent Biologics announced that Jaypirca (pirtobrutinib), a highly selective non-covalent Bruton’s...

TipRanks 1d
Eli Lilly, Nvidia Launch LillyPod: Pharma’s First ‘AI Factory’ in Indianapolis

Drug giant Eli Lilly (LLY) and chip giant Nvidia (NVDA) opened LillyPod, the pharmaceutical industry’s most powerful supercomputer, in Indianapolis yesterday. T...

Nasdaq 2d
Why Shares of Novo Nordisk Stock Sank (Again) This Week

Key Points Novo Nordisk lost another head-to-head trial against Eli Lilly. The company is cutting prices on weight-loss drugs in 2026. The stock looks cheap,...

Why Shares of Novo Nordisk Stock Sank (Again) This Week
Benzinga 2d
Eli Lilly's New Oral Weight Loss Drug Outperforms Semaglutide, Eyes Potential US Approval In Q2

Eli Lilly and Co. (NYSE:LLY) shares are down on Thursday. The company announced promising results for its oral GLP-1 medication, orforglipron. On Thursday, the...

Eli Lilly's New Oral Weight Loss Drug Outperforms Semaglutide, Eyes Potential US Approval In Q2
Simply Wall St 2d
Eli Lilly’s Orforglipron Trial Data Reshapes GLP-1 Growth Story

Eli Lilly's orforglipron, an oral GLP-1 therapy, outperformed oral semaglutide in the Phase 3 ACHIEVE-3 trial for adults with type 2 diabetes on metformin. The...

Eli Lilly’s Orforglipron Trial Data Reshapes GLP-1 Growth Story
TipRanks 2d
Eli Lilly publishes ACHIEVE-3 trial results in The Lancet

Eli Lilly (LLY) announced results from ACHIEVE-3, the first head-to-head Phase 3 trial evaluating the safety and efficacy of orforglipron, a small molecule oral...

The Motley Fool 3d
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know.

Eli Lilly has seen revenue and earnings soar in recent years. One of the biggest growth markets in the pharmaceutical industry today is that of weight loss dru...

Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know.

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.